IBRX ImmunityBio, Inc.

NEUTRAL Impact: 4/10 8-K
Horizon days Filed Apr 6, 2026 Processed 2mo ago SEC 0001193125-26-142932
8-K context-dependent: Items 7.01
Latest settled — T+20d
IBRX ▲ +4.94% at T+20d
NEUTRAL call ✓ call won +4.94% · α vs SPY -4.04% · entry $7.08 → $7.43
Next anchor: T+60d in 18d
Currently $7.10 · +0.28% from $7.08 entry
Entry anchored
Apr 6, 07:53 AM ET
via Databento tick
T+1d
-3.11%
call -3.11% · α -3.17%
$6.86
settled 2mo ago
T+5d
+3.11%
call +3.11% · α -1.03%
$7.30
settled 2mo ago
T+20d
+4.94%
call +4.94% · α -4.04%
$7.43
settled 6w ago
T+60d
call — · α —
in 18d

Price Chart

Loading chart...

Executive Summary

ImmunityBio submitted a comprehensive response to an FDA warning letter regarding promotional materials for its drug ANKTIVA, confirming a cited television ad was never aired and removing a podcast under review. The company is implementing enhanced compliance measures, including executive training and external oversight.

Actionable Insight

Monitor for any follow-up from the FDA, as regulatory compliance issues in biotech can escalate. While the immediate risk appears mitigated by the company's response, continued scrutiny could impact investor sentiment or future promotional strategies.

Key Facts

  • FDA issued a Warning Letter on March 13, 2026, concerning promotional materials for ANKTIVA.
  • ImmunityBio confirmed the cited television advertisement was never broadcast or disseminated.
  • The company removed the identified podcast from its website and requested removal from third-party platforms.
  • Corrective actions include mandatory executive training, expanded Promotional Review Committee (PRC) protocols, and engagement of external regulatory counsel.
  • The statements in question were made during a podcast by Founder Dr. Patrick Soon-Shiong and were described as aspirational and forward-looking.

Financial Impact

No direct financial impact disclosed. No fines, penalties, or material financial adjustments were mentioned.

Risk Factors

  • Potential for further FDA action if compliance concerns are not fully resolved.
  • Reputational risk from regulatory scrutiny, which could affect physician or patient confidence in the company or its product.
  • Risk of future non-compliance if internal controls are not effectively strengthened.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-142932
Document: d70606dex991.htm0001193125-26-142932
Document: 0001193125-26-142932-index-headers.html0001193125-26-142932
Document: 0001193125-26-142932-index.html0001193125-26-142932
Document: 0001193125-26-142932.txt0001193125-26-142932
4 reports for IBRX
Performance horizon
67% Hit rate 2 of 3 directional calls best @ T+20▲ +12.03%Apr 9, 2026
Filters
Rows
Reports for IBRX — sortable, filterable
Type Now
May 18, 2026
25d ago
8-K
BULLISH ★ 5/10
$7.76 $7.94▲ +2.26%▲ +0.01%$7.10 (−8.51%)
Apr 9, 2026
9w ago
8-K
BULLISH ★ 8/10
$7.48 $7.25▼ −3.07%▼ −6.26%$7.10 (−5.08%)
Apr 6, 2026
9w ago
8-K
NEUTRAL ★ 4/10
$7.08 $7.30▲ +3.11%▼ −1.03%$7.10 (+0.28%)
Feb 28, 2026
15w ago
Institutional Cluster
BULLISH ★ 6/10
$10.44 $8.45▼ −19.06%▼ −17.85%$7.10 (−31.99%)
Showing 4 of 4

US Market Status

Market Closed — Opens Mon (48h 48m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access